Skip to main content Back to Top


Hydroxyamphetamine Hydrobromide and Tropicamide Ophthalmic Solution

Reason for the Shortage

    • Akorn had Paremyd on shortage due to manufacturing delays.
    • No clinical trial data were found to support the use of Paremyd in the diagnosis of Horner Syndrome.

Available Products

    • Paremyd ophthalmic solution, Akorn, 1% hydroxyamphetamine hydrobromide and 0.25% tropicamide, 15 mL bottle, 1 count, NDC 17478-0704-12

Estimated Resupply Dates

    • Akorn has Paremyd ophthalmic solution available.


Updated April 25, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 13, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins